TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). (Q46635338)

23 December 2017

title

TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). (English)

1 reference

23 December 2017

0 references

1 reference

Risini D Weeratna

1 reference

23 December 2017

Shawn R Makinen

series ordinal

1 reference

23 December 2017

Michael J McCluskie

series ordinal

1 reference

23 December 2017

Heather L Davis

series ordinal

1 reference

23 December 2017

language of work or name

English

0 references

publication date

18 July 2005

1 reference

23 December 2017

number of pages

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

23 December 2017

volume

1 reference

23 December 2017

issue

1 reference

23 December 2017

page(s)

5263-5270

1 reference

23 December 2017

Innate Immunity: The Virtues of a Nonclonal System of Recognition

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Toll-like receptors: critical proteins linking innate and acquired immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Toll-like receptors and their signaling mechanism in innate immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

A Comparative Study of the Generation of Dendritic Cells from Mobilized Peripheral Blood Progenitor Cells of Patients Undergoing High-Dose Chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Human monocyte-derived dendritic cells induce naive T cell differentiation into T helper cell type 2 (Th2) or Th1/Th2 effectors. Role of stimulator/responder ratio

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Dendritic cell subsets: the ultimate T cell differentiation decision makers?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential toll-like receptor ligation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Controlling the Toll road to dendritic cell polarization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Identification of hTLR10: a novel human Toll-like receptor preferentially expressed in immune cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

A family of human receptors structurally related to Drosophila Toll

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

TLR6: A novel member of an expanding toll-like receptor family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Involvement of ERK, p38 and NF-kappaB signal transduction in regulation of TLR2, TLR4 and TLR9 gene expression induced by lipopolysaccharide in mouse dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Murine TOLL-like receptor 4 confers lipopolysaccharide responsiveness as determined by activation of NF kappa B and expression of the inducible cyclooxygenase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

A Toll-like receptor recognizes bacterial DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

CpG motifs in bacterial DNA trigger direct B-cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Activation of human B cells by phosphorothioate oligodeoxynucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor‐α‐mediated shock

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Adjuvant activities of immune response modifier R-848: comparison with CpG ODN

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Interleukin-12 and its role in the generation of TH1 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

IL-12: initiation cytokine for cell-mediated immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

The Toll‐like receptor 7 (TLR7)‐specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Selective stimulation of murine cytotoxic T cell and antibody responses by particulate or monomeric hepatitis B virus surface (S) antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

A soluble lymphocyte activation gene-3 molecule used as a vaccine adjuvant elicits greater humoral and cellular immune responses to both particulate and soluble antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

CpG-DNA aided cross-presentation of soluble antigens by dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

CpG oligodeoxynucleotide induction of antiviral effector molecules in sheep

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

CpG DNA induces stronger immune responses with less toxicity than other adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.024

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2005.06.024

1 reference

23 December 2017

1 reference

23 December 2017